Physician profile
James Lyle Comadoll
NPI 1013963446
$1,141,676.31
in general payments reported to CMS, 2019-2025
5 companies · $166K in 2025
The $166K reported for 2025 was more than what 98% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142K · 2020: $118K · 2021: $185K · 2022: $150K · 2023: $212K · 2024: $169K · 2025: $166K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $266K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $167K · Travel and Lodging: $103K · Food and Beverage: $9,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $266,331.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $167,364.31 |
| Travel and Lodging | $103,090.18 |
| Food and Beverage | $9,823.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,120,144.78 | 2019-2025 | Real Intelligence, Journey II, Tandem |
| Medical Device Business Services, INC. | $21,239.00 | 2019-2020 | |
| Trice Medical, INC. | $200.00 | 2019 | |
| Depuy Synthes Sales INC. | $56.11 | 2019 | |
| Organogenesis INC. | $36.42 | 2023 | Puraply |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Comadoll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.